SCHEMBL7902134

SCHEMBL7902134

CC(C)(C)OC(=O)CC[C@H](NC(=O)Oc1ccc(N(CCO)CCO)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.34
PPARA Q07869 4/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ABCB1 P08183 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 2/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
ACHE P22303 1/20 0.32
ELANE P08246 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
PPARD Q03181 2/20 0.32
LTA4H P09960 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
P2RY12 Q9H244 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894784 0.91 PPARG (0.34) PPARGPPARANFKB1NFKB2RELA
SCHEMBL7903878 0.91 PPARG (0.34) PPARGPPARANFKB1NFKB2RELA
SCHEMBL7906466 0.86 ABCB1 (0.32) PPARGPPARANFKB1NFKB2RELA
SCHEMBL7900272 0.85 KMT2A (0.41) LTA4HMEN1KMT2AALDH1A1LMNA
SCHEMBL8509781 0.83 LMNA (0.33) ABCB1KMT2ALMNACACNA1B
SCHEMBL6036281 0.81 KMT2A (0.43) PPARGPPARANFKB1NFKB2RELA
SCHEMBL6036278 0.81 KMT2A (0.43) PPARGPPARANFKB1NFKB2RELA
SCHEMBL6036686 0.80 PPARA (0.40) PPARGPPARAABCB1TDP1KDM4E
SCHEMBL6036690 0.80 PPARA (0.40) PPARGPPARAABCB1TDP1KDM4E
SCHEMBL7903853 0.79 PPARG (0.48) PPARGPPARANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6277880-B1 ANTIBODY DIRECTED ENZYME PRODUG THERAPY ZENECA LIMITED (GB) 2001-08-21 US disclosed
US-5981791-A High purity N-(4-[N,N-bis(2-iodoethyl)amino]phenoscycarbonyl)-L-glutamic acid ZENECA LIMITED (GB) 1999-11-09 US disclosed
US-5958971-A PRODRUGS OF NITROGEN MUSTARD, AN ANTICARCINOGENIC AND TUMOR AGENT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT); BIOCHEMICAL CONJUGATION ZENECA LIMITED (GB) 1999-09-28 US disclosed
EP-0651740-B1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LTD (GB) 1998-10-21 EP disclosed
US-5714148-A PRODRUGS WHICH ARE SUBSTRATES FOR CARBOXYPEPTIDASE G2 AND YIELD ACTIVE CYTOTOXIC DRUGS ZENECA LIMITED (GB) 1998-02-03 US disclosed
US-5660829-A DEESTERIFYING COMPOUND TO FORM N-(4(N,N-BIS(2-CHLOROETHYL) AMINO)PHENOXYCARBONYL)-L-GLUTAMIC ACID-GAMMA-(3,5-DICARBOXY)ANILIDE ZENECA LIMITED (GB) 1997-08-26 US disclosed
US-5587161-A TWO COMPONENT SYSTEM INCLUDING ANTIBODY OR ANTIGEN BINDING FRAGMENT CONJUGATED TO CARBOXYPEPTIDASE G ENZYME, COMPOUND CONVERTIBLE TO CYTOTOXIC DRUG UNDER INFLUENCE OF ENZYME ZENECA LIMITED (GB) 1996-12-24 US disclosed
EP-0651740-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1995-05-10 EP disclosed
US-5405990-A For use in antibody directed enzyme prodrug therapy; cytotoxic parent nitrogen mustard; antitumor agents ZENECA LIMITED (GB) 1995-04-11 US disclosed
WO-1994002450-A1 AMINO ACID LINKED NITROGEN MUSTARD DERIVATIVES AND THEIR USE AS PRODRUGS IN THE TREATMENT OF TUMOURS ZENECA LIMITED (GB) 1994-02-03 WO disclosed